GuidelinePloS one2009
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
Guideline in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 475 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
475 citing papers in PubMed, 5 syntheses or guidelines pooled it, 957 citations in OpenAlex.
- HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis.Viruses · 2024Pooled it
- Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review.The Lancet. Microbe · 2022Pooled it
- Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2021Pooled it
- Prevalence of pretreatment HIV drug resistance in key populations: a systematic review and meta-analysis.Journal of the International AIDS Society · 2020Pooled it
- HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.The Lancet. Infectious diseases · 2018Pooled it
- Emergence of two novel HIV-1 Circulating Recombinant Forms (CRF190_0708 and CRF191_0708): molecular characterization and clinical insights from a five-year study in Yunnan, China.BMC microbiology · 2026Trial
- Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART).Journal of the International AIDS Society · 2022Trial
- Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.The Journal of infectious diseases · 2022Trial
- High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up.AIDS research and therapy · 2019Trial
- Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.The Journal of antimicrobial chemotherapy · 2019Trial
- Transmitted and pretreatment drug resistance among 69 HIV-1 CRFs in China: the first systematic analysis.Emerging microbes & infections · 2026Article
- Non-Canonical Binding of Nelfinavir in HIV-1 Protease Variants Reveals Structural Mechanisms of Antiretroviral Resistance.Viruses · 2026Article
- Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023).Open forum infectious diseases · 2026Article
- Similar Changes in Proviral Landscapes Over 10 Years in 40 Individuals With Diverging HIV Reservoir Dynamics and Viral Load Kinetics.Open forum infectious diseases · 2026Article
- Article
- Detection of HIV-1 Resistance Mutations to Antiretroviral Therapy and Cell Tropism in Russian Patients Using Next-Generation Sequencing.Pathogens (Basel, Switzerland) · 2026Article
- Real-world Prevalence of Nonintegrase INSTI Resistance-Associated Mutations and Virological Outcomes in People Who Have Recently Acquired HIV-1 in the United Kingdom.The Journal of infectious diseases · 2026Article
- Evaluating HIV-1 Transmitted Drug Resistance and Clustering in Newly Diagnosed Patients in Romania (2019-2022).Viruses · 2026Article
- Molecular transmission network analysis of HIV-1 among older adults in Central China: a cross-sectional study in Shaodong City.Frontiers in microbiology · 2026Article
415 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 9 countries.
Funding
Abstract
Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programs. To accurately compare transmitted drug resistance rates across geographic regions and times, the World Health Organization has recommended the adoption of a consensus genotypic definition of transmitted HIV-1 drug resistance. In January 2007, we outlined criteria for developing a list of mutations for drug-resistance surveillance and compiled a list of 80 RT and protease mutations meeting these criteria (surveillance drug resistance mutations; SDRMs). Since January 2007, several new drugs have been approved and several new drug-resistance mutations have been identified. In this paper, we follow the same procedures described previously to develop an updated list of SDRMs that are likely to be useful for ongoing and future studies of transmitted drug resistance. The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.